SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from Riot Platforms, Inc. (RIOT) (CIK 0001167419) (RIOT) — Jul 7, 2010

Riot Platforms, Inc. (RIOT) (CIK 0001167419)
Date: July 7, 2010 · CIK: 0001167419 · Accession: 0001079973-10-000747

AI Filing Summary & Sentiment

File numbers found in text: 001-33675

Referenced dates: June 30, 2010

Date
July 7, 2010
Author
/s/
Form
CORRESP
Company
Riot Platforms, Inc. (RIOT) (CIK 0001167419)

Letter

appy_corresp.htm

Correspondence

Mary J. Mullany

Direct: 215.864.8631

Fax: 215.864.8999

mullany@ballardspahr.com

July 7, 2010

Via EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

F Street NE

Washington, DC 20549

Attn: Frank Wyman

Re:

AspenBio Pharma, Inc.

Form 10-K for the Fiscal Year Ended December 31, 2009

Filed March 9, 2010

Form 10-K/A for the Fiscal Year Ended December 31, 2009

Filed April 28, 2010

File No. 001-33675

Ladies and Gentlemen:

On behalf of AspenBio Pharma, Inc. (the “Registrant”), we acknowledge receipt of the Staff’s letter, dated June 30, 2010, with comments related to the above-referenced filings.

The Registrant intends to respond to the Staff’s letter by July 30, 2010.

Sincerely,
/s/
Mary J. Mullany

Show Raw Text
CORRESP
1
filename1.htm

    appy_corresp.htm

    Correspondence

            Mary
      J. Mullany

Direct:
215.864.8631

              Fax:
      215.864.8999

              mullany@ballardspahr.com

July 7, 2010

      Via
EDGAR

                United
      States Securities and Exchange Commission

                Division
      of Corporation Finance

                100
      F Street NE

                Washington,
      DC 20549

                Attn:  Frank
      Wyman

Re:

                AspenBio
      Pharma, Inc.

                  Form
      10-K for the Fiscal Year Ended December 31, 2009

                    Filed
      March 9, 2010

                      Form
      10-K/A for the Fiscal Year Ended December 31, 2009

                        Filed
      April 28, 2010

                          File No.
      001-33675

Ladies and Gentlemen:

      On behalf
of AspenBio Pharma, Inc. (the “Registrant”), we acknowledge receipt of the
Staff’s letter, dated June 30, 2010, with comments related to the
above-referenced filings.

      The
Registrant intends to respond to the Staff’s letter by July 30,
2010.

Sincerely,

      /s/
Mary J. Mullany

      Mary J.
Mullany

MJM/cdr

cc:

                Stephen
      T. Lundy

                  Jeffrey
      G. McGonegal

        Atlanta
|  Baltimore |  Bethesda |  Denver
|  Las Vegas |  Los Angeles |  New Jersey
|  Philadelphia |  Phoenix |  Salt Lake City
|  Washington, DC |  Wilmington